Introduction
Pneumocystis jirovecii is an opportunistic fungus localized in the alveoli of the lung that causes pneumonia. Pneumocystis pneumonia (PjP) remains a frequent cause of morbidity and mortality in immunocompromised patients relationship between the number of blood CD4 ϩ lymphocytes and the risk of subsequent PjP [8] . CD8 ϩ T cells, which are recruited to the lung in large numbers in response to P. jirovecii infection, have been associated with lung injury in murine models [9 -11] . Several observations support an important role for AM in the successful host response to P. jirovecii [12] . Rats selectively depleted of AM were found to have impaired clearance of P. jirovecii [5] . AMs require cytokine activation to maximize their activity [13, 14] and therefore a cytokine and chemokine network is necessary for P. jirovecii clearance by activation of these cellular effectors. Different studies carried out principally in murine models, have shown an important role for TNF-α or IL-10, two opposing cytokines in the T helper response [15, 16] . The characterization of another novel T helper subtype, Th17 cells, has complicated the basic Th1/Th2 model of P. jirovecii infection [17] .
Even if the alveolar environment seems to be essential in P. jirovecii infection pathophysiology, much information needs to be clarifi ed and there is a need for an overall view of the evolution of the immune response during this disease in man. The aim of our study was to examine the changes in the alveolar cytokinic and cellular environment in P. jirovecii -infected patients according to the P. jirovecii alveolar burden.
Materials and methods

Patients ' specimens
Studies of fresh bronchoalveolar lavage (BAL) samples that had been submitted to the Parasitology-Mycology unit of the Toulouse University Hospitals (France) were conducted from November 2007 to April 2008. The clinical unit systematically transmitted these samples to the different laboratories of the Toulouse Hospitals for investigation or pneumopathies tests. BAL fl uid was recovered and treated according to the usual routine protocols of the Toulouse Hospitals. Investigations were performed in the Parasitology-Mycology unit for Toxoplasma gondii (direct examination and PCR) and different fungi (direct examination, culture and identifi cation) including P. jirovecii (direct examination and PCR). In the Virology unit, real-time PCR assays were used to detect the most frequent viral agents of infections of the lungs (1 and 2 Herpes simplex virus, Varicella zona virus, Infl uenza virus, Cytomegalovirus, Rhinovirus and Adenovirus), whereas direct examination, culture and identifi cation were conducted for potential pathogenic bacteria in the Bacteriology unit. In the Cytology unit, a total and differential leukocyte count was done on the BAL.
All sequential BAL samples found to be positive for P. jirovecii DNA were selected during the six month period for this investigation. To choose the negative controls, we decided to include in our analysis all the fi rst P. jirovecii DNA negative samples after each positive patient.
Immunosuppression and its causes was analysed for all P. jirovecii -positive or negative patients selected for this study. Patients were considered as immunocompromised when an immunosuppressive therapy was carried out (chemotherapy for solid or hematologic cancer, treatment for systemic disease, immunosuppressive therapy post transplantation) or when they were positive for HIV with blood lymphocyte CD4 ϩ T cells Ͻ 500/mm 3 .
To determine the infl uence of immunosuppression or P. jirovecii infection on the different parameters, patients were classifi ed according to two criteria, i.e., the immunosuppression status (IC) and the presence of P. jirovecii DNA (Pnj) in the BAL fl uid. The patients positive for P. jirovecii but without immunosuppression were excluded from this study. Among the remaining patients, three groups of patients were incorporated into the study consisting of two control groups and one study group. The fi rst control group was composed of patients without P. jirovecii DNA in their BAL and without immunosuppression [IC(-)/ Pnj(-)], the second control group contained patients without P. jirovecii DNA but who were immunosuppressed [IC( ϩ )/Pnj(-)] and the third (study group) contained only immunocompromised patients with P. jirovecii DNA [IC( ϩ )/Pnj( ϩ )]. The patients in the latter group [IC( ϩ )/ Pnj( ϩ )] were ranked according to their PCR cycle threshold (Ct) which was refl ective of the alveolar fungal burden of P. jirovecii , as described in a previous study [18] . Thus, these patients were further sub-divided into three groups, i.e., PCR with Ct Ն 28 (low fungal burden: improbable PjP), PCR with 22 Յ Ct Ͻ 28 (moderate fungal burden: possible PjP) and PCR with Ct Ͻ 22 (high fungal burden: authentic PjP) [18] . Patient identifi ers were eliminated from all clinical and biological data.
BAL
Briefl y, after topical 2% lidocaine anesthesia of the oropharynx, a fi beroptic bronchoscope was passed into the airways and wedged in a segment of the right middle lobe. BAL was performed by instilling 150 ml of warm saline solution (0.9%), followed by gentle suction. The BAL obtained was sent to the different laboratories for routine evaluation of pathogens (virus, bacteria, mycobacteria, fungus, and parasites).
(1 ml PBS: 438 g for 5min), an appropriate amount of secondary antibody (goat IgG PE anti-mouse IgG2b) was added and incubated for 30 min, followed by another wash. All analyses were performed on a FACScan fl ow cytometer (BD Biosciences, San Jose, USA) using CellQuest software (BD Biosciences, San Jose, USA). The AM population was gated using CD11b labelling. Fluorescence in the macrophage gate was assessed and quantifi ed in arbitrary units as mean fl uorescence intensity (MFI). For every patient, the MFI was assessed for each antibodylabelled cell suspension and divided by the MFI of the same isotype.
Real-time PCR assay
A real-time PCR assay to detect P. jirovecii DNA was performed with probes labelled with fl uorescein and Red 640 (FRET), as described previously [18] as an adaption of the Larsen et al . method [20] . All acquired fl uorescence data were analyzed and the quantifi cation of the P. jirovecii DNA was represented by the cycle threshold (Ct) measured by the LC software. A Ct value was reported for each positive sample.
Cytokine measurement in BAL
The lavage fl uid was centrifuged for 5 min at 2594 g to remove cells and P. jirovecii. Supernatants were stored at −80°C until used. IL-6, IL-10, IL-17, TGF-β and TNF-α were measured by using commercially available ELISA assays (ELISA BD OptEIA, BD Biosciences, San Jose, USA for IL-6, IL-10 and TNF-α ; ELISA eBIOSCIENCE, San Diego, USA for IL-17and TGF-β ) according to the manufacturer ' s instructions.
Statistical methods
Bivariate analysis was performed using the χ2 test or Fisher ' s exact test to compare patient characteristics in each group. The odds ratio and 95% confi dence intervals (OR [ 95% CI]) were used to describe associated factors. For continuous parameters, the data distribution was found to be non-Gaussian. The distributions were displayed as median along with interquartile ranges (med [IQR] ). These data were analyzed using the non-parametric MannWhitney rank sum test for two group comparisons. The relationships between two variables were analyzed by the Pearson product-moment correlation. A comparison was considered statistically signifi cant if the P value was Յ 0.05.
All tests were performed using the SigmaStat (2.03) statistical program (SigmaStat, Heame Scientifi c Software, Chicago, USA). determine precisely the contents of the examined alveolus (cells, cytokines, P. jirovecii DNA), the urea technique was carried out using the Rennard method [19] . Urea passes freely from blood to ALF and vice versa [19] . Therefore, the concentration of urea in the serum and in the ALF is equal. Urea was quantifi ed in serum ([U]se) and in BAL fl uids ([U]BAL) by an automated enzymatic method (Olympus AU2700 with Olympus Urea kit, Olympus diagnostics, Melville, USA). Since the volume of saline solution for the lavage was known (Vinj), it was possible to determine the volume of ALF for each patient through the use of the formula VALF ϭ (Vinj
. The urea concentration in the serum was divided by the concentration in BAL fl uid to determine the dilution (D) of the ALF by the saline solution. As the concentrations of cells, cytokines or P. jirovecii DNA were known in the BAL, it was possible to determine the absolute quantity of these elements in the explored alveolus for each patient by multiplying the BAL concentration by D and VALF. Cells were expressed as the number of cells, cytokines as quantity (pg) and P. jirovecii DNA as cycle threshold (Ct).
Total and differential leukocyte counts and cell characterization by fl ow cytometry in blood and BAL
In blood, total and differential leukocytes counts were performed in the haematology laboratory with automated routine haematology analyzers: Beckman Coulter LH 750 (Beckman Coulter, Miami, USA) and Sysmex XE-2100 (TOA Medical Electronics Co., Kobe, Japan).
In the BAL, a total cell count was done in the cytology unit using a Malassez hemocytometer. Then each BAL fl uid specimen was cytospun (95 g for 8 min) and the smear obtained stained by the May Gr ü nwald Giemsa (MGG) method to numerate the patient ' s alveolar cells.
Lymphocytes were characterized in BAL and blood by the immunology laboratory using standard fl ow cytometry following routine methods. CD3-FITC, CD4-APC and CD8-PE monoclonal antibodies (Multiset BD, BD Biosciences, San Jose, USA) were used with BD TruCOUNT tubes (BD Biosciences, San Jose, USA) according to the manufacturer ' s instructions. Analyses were performed on a FACScalibur fl ow cytometer (BD Biosciences, San Jose, USA).
AMs in ALF were characterized using Dectin-1, Mannose Receptor, CD14 and CD36 -monoclonal antibodies. After centrifugation of the BAL (438 g for 5min), monoclonal antibodies directed against Dectin-1(IgG2b mice; R & D Systems, Minneapolis, USA), the mannose receptor (IgG1 mice-APC; Serotec, Oxford, UK), CD36 (IgM mouse-FITC) and CD14 (IgG2a mouse-PerCPCy5.5; BD Biosciences, San Jose, USA) were added to each pellet and incubated in the dark for 30 min. After one further wash
Results
Patient characteristics (Table 1)
After analysis for the presence of P. jirovecii DNA, 135 BAL samples collected from November 2008 to April 2009 were initially selected for inclusion in this study. Seventy of the samples were positive for P. jirovecii DNA, while specimens of 65 P. jirovecii -negative patients were included to serve as controls. The median age of all these patients was 56.7 years IQR [41.8; 65.7] and the sex ratio (M:F) was 1.75. According to the criteria of inclusion described in the methods section, six patients with a positive PCR for P. jirovecii , but without identifi able immunosuppression factors were excluded from the investigation. All the latter patients had very low P. jirovecii burden (Ct Ͼ 28) clinically compatible with colonization. The remaining 129 patients were classifi ed in one of the three groups, i.e., a control group of non-immunocompromised patients without P. jirovecii DNA [IC(-)/Pnj(-)] (group 1 with 32 patients), a second control group of immunocompromised patients without P. jirovecii DNA [IC( ϩ )/ Pnj(-)] (group 2 of 33 patients) or a third study group of only immunocompromised patients with P. jirovecii DNA [IC( ϩ )/ Pnj( ϩ )] (group 3 composed of 64 patients).
In the two immunocompromised groups (group 2 and 3), the four main sources of immunosuppression were (a) cancerous malignancies and associated chemotherapy [lymphoma, myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), solid tumor (oesophagus, cerebral, epidermoid carcinoma)], (b) HIV-infection with blood lymphocyte CD4 ϩ T cells Ͻ 500 mm 3 , (c) transplantation and associated therapy (bone marrow, kidney, liver, heart, lung), and (d) systemic or autoimmune disease and associated treatment (rheumatoid arthritis, temporal arteritis, Wegener ' s granulomatosis, myasthenia, idiopathic thrombocytopenic purpura, sarcoidosis, mixed connective tissue disease, Sweet ' s syndrome). There were no significant differences among the patients in the two groups in terms of age, sex, presence of treatment or prophylaxis anti-P. jirovecii or cause of immunosuppression (HIV, immunosuppressant treatment post-graft or transplant, immunosuppressant treatment for autoimmune or systemic disease, cancer/chemotherapy). The ratio among patients with or without viral, fungal and bacterial co-infection was not signifi cantly different between the two groups.
Moreover, there were no signifi cant differences among the patients in the two groups without detectable P. jirovecii [IC(-)/Pnj(-) (group 1) and IC( ϩ )/Pnj(-) (group 2) groups] relative to age, sex, or viral, fungal and bacterial co-infection. Nevertheless, treatment or anti-P. jirovecii prophylaxis before BAL sample analysis, were statistically lower in the IC(−)/Pnj(−) than in the IC( ϩ )/Pnj(-) group [IC(-)/ Pnj(-): 3.5% vs IC( ϩ )/Pnj(-): 48.5%].
Alveolar leukocytes changes among P. jirovecii-infected patients
The number of alveolar leukocytes was not statistically different in the three groups of IC(-)/Pnj(-), IC( ϩ )/Pnj(-) and IC( ϩ )/Pnj( ϩ ) patients (data not shown). However, there was an inverse correlation between the P. jirovecii burden and alveolar leukocyte number (Fig. 1A) .
Differential leukocyte counts did not show signifi cant differences among the samples from the three groups with respect to alveolar neutrophil and eosinophils polynuclear cell numbers (data not shown). The number of alveolar macrophages (AM) was signifi cantly lower in the IC( ϩ )/Pnj( ϩ ) group compared with the IC( ϩ )/Pnj(-) group (15, 384 IQR [7962; 33684] vs 26,985 IQR [17,743; 61,058] ) but no signifi cant difference was observed between the IC(−)/Pnj(−) and the IC( ϩ )/ Pnj(-) groups (Fig. 1B) . The decrease in macrophages affected more specifi cally the patients with high (13, 334 IQR [5, 101; 23, 710] ) or middle P. jirovecii burden (10, 803 IQR [8, 261; 26, 992] ) (Fig. 1B) but there was no correlation between the AM number and fungal burden (data not shown). Peripheral blood leukocytes were analysed to determine whether the macrophage count was decreased only in lung alveoli. The peripheral blood monocyte count was not signifi cantly different in the three groups (data not shown), suggesting that the decline in monocytes/macrophages was localized to the lung.
The alveolar lymphocyte count was statistically higher in the IC( ϩ )/Pnj( ϩ ) than in the IC( ϩ )/Pnj(-) group (4, 858 IQR [1, 057; 14, 562] vs 1,469 IQR [789; 2,896] ) (Fig. 1C) . There was no signifi cant difference between IC(-)/Pnj(-) and IC( ϩ )/Pnj(-) groups. In the IC( ϩ )/Pnj( ϩ ) group, the increase was specifi c to the patients with a low (7, 017 IQR [1, 385; 21, 649] ) or middle P. jirovecii burden (10, 091 IQR [4, 340; 33, 079] ) (Fig. 1C) . This increase was specifi cally observed in the lungs as the lymphocyte count in the blood was not signifi cantly different between the two immunocompromised groups [IC( ϩ )/Pnj(-) and IC( ϩ )/ Pnj( ϩ )]. A decrease was nevertheless observed in the IC( ϩ )/Pnj(-) group compared with the IC(-)/Pnj(-), quite probably as a result of immunosuppression (data not shown). Therefore, the alveolar lymphocyte count was inversely correlated with the P. jirovecii burden in IC( ϩ )/ Pnj( ϩ ) patients (Fig. 1D) . The blood lymphocyte count was not correlated with pulmonary P. jirovecii burden (data not shown). Thus, lymphocyte changes appeared to be a local pulmonary phenomenon.
Aveolar lymphocyte profi les among P. jirovecii-infected patients
The blood and alveolar CD8 ϩ T lymphocyte counts were determined. The number of alveolar CD8 ϩ T lymphocytes was similar in the two groups without detectable P. jirovecii DNA ( Fig. 2A) Fig. 2A) . Thus, the presence of P. jirovecii in the lung led to an increase in alveolar CD8 ϩ T lymphocytes. Nevertheless, the P. jirovecii burden was not correlated with alveolar CD8 ϩ T lymphocyte counts (data not shown) as the latter were increased whatever the burden. This result was not linked to HIV status since a high level of CD8 ϩ was often found (data not shown) with P. jirovecii ( ϩ )/HIV(-) patients. The blood CD8 ϩ lymphocyte count was not statistically different in the three groups and not correlated with fungal burden (data not shown). Alveolar and blood CD4 ϩ T lymphocytes were evaluated. These cells evolve in the same way as alveolar lymphocytes. There was no signifi cant difference between the two groups IC(-)/Pnj(-), IC( ϩ )/Pnj(-) but the alveolar CD4 ϩ lymphocyte count was statistically higher in the IC( ϩ )/ Pnj( ϩ ) than in IC( ϩ )/Pnj(-) group (2, 544 IQR [758; 10, 761] vs 435 IQR [242; 1,331]) (Fig. 2B ). This increase was specifi c to the patients with a low (3, 973 IQR [880; 22, 049] ) or middle P. jirovecii burden (6, 073 IQR [4, 178; 29, 921] ) (Fig. 2B) . Moreover, the number of CD4 ϩ T lymphocytes was inversely correlated with the fungal burden in immunocompromised P. jirovecii infected patients (Fig. 2C ). This inverse correlation was also obtained with the percentage of alveolar CD4 ϩ T lymphocytes (Fig. 2D ) and the CD4 ϩ /CD8 ϩ ratio (Fig. 2E) . In blood, no increase in CD4 ϩ cells was observed, i.e., in the two groups of immunocompromised patients [IC( ϩ )/Pnj( ϩ ) and IC( ϩ )/ Pnj(−)], the CD4 ϩ T lymphocyte count was not different whatever the P. jirovecii burden, but was logically higher in the IC(−)/Pnj(−) patients than in the IC( ϩ )/Pnj(-) group (data not shown).
Changes in AM receptor expression in P. jirovecii-infected patients
CD14 and CD36 expression were very low on the AM of all the patients (data not shown). The mannose receptor was expressed but there was no signifi cant difference among the three groups for this marker (Fig. 3A) . However, Dectin-1 had a signifi cantly higher expression on the AM of the IC( ϩ )/Pnj( ϩ ) group than on the IC( ϩ )/Pnj(-) group (1.87 IQR [1.48; 2.57] vs 1.40 IQR [1.18; 1.65]) (Fig. 3B) . There was no signifi cant difference between the IC(-)/Pnj(-) and IC( ϩ )/Pnj(-) groups suggesting that this increase was related to P. jirovecii .
Alveolar cytokine profi les from P. jirovecii-infected patients (Table 2)
The levels of TNF-α , IL-10, TGF-β and IL-17 were not statistically different between the three groups IC(-)/Pnj(-), IC( ϩ )/Pnj(-) and IC( ϩ )/Pnj( ϩ ) ( Table 2 ).
The IL-6 level was not different between the IC(-)/ Pnj(-) and IC( ϩ )/Pnj(-) groups but was statistically higher in the IC( ϩ )/Pnj( ϩ ) than in the IC( ϩ )/Pnj(-) ( Table 2 ). This dramatic increase in the IL-6 level was highlighted among the IC( ϩ )/Pnj( ϩ ) patients whatever the fungal burden (data not shown).
Discussion
The results of the present study show that human P. jirovecii infection was linked to changes in the local alveolar microenvironment, particularly in terms of cell numbers and in cytokine levels. These data were obtained by comparing different groups of patients with or without P. jirovecii infections. In this study, one of the diffi culties was to separate changes in the alveolar environment induced by the pathogen from those caused by immunosuppression. To solve this problem, three groups were defi ned among the patients recruited. We compared a group of non-immunocompromised patients without P. jirovecii infections with those that were immunocompromised to determine the infl uence of immunosuppression on the factors studied. Then, a group of immunocompromised patients with P. jirovecii infections was compared with a similar group without evidence of such infections to study the specifi c infl uence of Pneumocystis on the alveolar environment. It would be interesting to subgroup patients with P. jirovecii according to the cause of the immunosuppression (HIV, transplantation, etc.) but the resultant patient numbers would probably be too small for accurate analysis. However, statistical analyses showed that the three groups consisted of the same proportion of HIV-positive patients, and those treated for cancer, transplantation or systemic disease. There was homogeneity within each group as to the etiology of immunosuppression that minimized the impact of this factor on the parameters studied. Another diffi culty was that patients infected by P. jirovecii were quite often coinfected with a second pathogen (bacteria, fungus or virus).
However, the data show that the three groups were homogenous relative to pulmonary infections other than P. jirovecii . In each group, the proportions of bacterial, viral and fungal infections were the same and so that reduced the infl uence of the other pathogen on the markers analyzed for P. jirovecii . , median of the population. The direct comparison of the concentrations of cellular or soluble material in the BAL among different patients is not ideal because of their different pulmonary status (oedema). In order to more accurately standardize the quantifi cation of the elements within the BAL, we decided to correct for the dilution of the alveolar component to take into account any eventual oedema. According to Dargaville et al . [21] , urea is the most appropriate choice of a marker since the lavage/plasma urea ratio appears to provide a meaningful estimate of ALF recovery even in the diseased lung. The volume of ALF (including the volume from an eventual oedema) and the BAL dilution was established for each patient to enable the determination of the absolute quantity of ALF components. Nevertheless, it is noteworthy to point out that directly using BAL concentrations without corrections (expressed as ' per ml of BAL ' ), would have provided the same results in the inter-group comparisons, as well as for the correlations.
To evaluate the evolution of the number of cells among immunocompromised P. jirovecii-infected patients, we determined the alveolar lymphocyte, macrophage and total leukocyte counts. Despite a constant alveolar total leukocyte number, we showed that during P. jirovecii infection, lymphocytes increased whereas at the same time, the AM decreased. In line with a previous study, our results confi rm the importance of these two cell types in the pathophysiology of P. jirovecii infection [12] . Moreover, although Vestbo et al . [22] observed a correlation in the , median of the population. lung interstitium between the amount of P. jirovecii and the accumulation of leukocytes, there was no data on this relationship in the alveolar environment where P. jirovecii was present and interacting directly with the immune cells. Our study demonstrated that the number of alveolar leukocytes (particularly AM and lymphocytes) was inversely associated with the P. jirovecii burden. Binding and phagocytosis of P. jirovecii by AM is a critical fi rst step in the initiation of the immune response and the eventual clearance of the organism [23] . Several studies have shown that the percentage of AM in BAL fl uid of AIDS patients with PjP was reduced [24 -26] . It is unknown whether this change was due to a decrease in the number of AM or an increase in other cell types. In the Dex-Pc rat model, Lasbury et al . determined that the absolute number of AMs was decreased in infected rats [27] . Using urea determinations, our study confi rms that during PjP, the absolute AM number was signifi cantly lower in patients with P. jirovecii infection whatever the cause of the immunosuppression (HIV or not). This is important data as some authors have shown that an increase in the numbers of alveolar macrophages was associated with a decreased mortality in animals [28] and man [29] . Moreover, the low AM count is linked to the presence of P. jirovecii and not to immunosuppression since there is no difference between the IC(-)/Pnj(-) and IC( ϩ )/Pnj(-) groups of patients. The reduced AM count is a localized pulmonary phenomenon as the blood monocyte count was similar between controls and the IC( ϩ )/Pnj( ϩ ) groups. The AM count is lowered only when patients present authentic (high fungal burden) or possible moderate fungal burden in PjP (Ct Ͻ 28). Nevertheless, we could not establish a direct correlation between the AM count and the fungal burden. Thus, we can conjecture that the presence of P. jirovecii is not directly linked to the AM decrease but rather that AM are indirectly adversely affected. This phenomenon may be explained by two different hypotheses. First, the AM decrease and the impairment of the function of these cells observed in HIV-infected individuals [30] or in animal models [31] (diminution of oxidative burst and phagocytosic response) may be one consequence of the CD4 ϩ T cell defi ciency (in number or activity). Indeed, AM activity requires lymphocyte cooperation, particularly of CD4 ϩ T cells. The latter secrete products such as IFNγ and coordinate the host infl ammatory response by recruiting and activating immune effector cells including monocytes and macrophages, which are responsible for elimination of the organism [3, 32] . On the other hand, the alteration in the number of the AM may also be directly due to P. jirovecii as described by Liao et al . in murine models [33] . Apoptosis of AM may be triggered by an increase in polyamine synthesis induced by P. jirovecii . This decrease in AM may, in a vicious circle mechanism, cause fungal multiplication in the alveolus which increases again the apoptosis. These two explanations (lack of immune stimulation and apoptosis) may be complementary to explain the pathophysiology of this phenomenon.
The uptake of P. jirovecii by macrophages occurs through multiple receptor systems, including mannose receptors that interact with the major surface glycoprotein (gp-A) existing on the surface of Pneumocystis [34] cells, and the interaction between P. jirovecii β-glucans and the dectin-1 receptor [35] . Koziel et al . [36] observed that AM isolated from HIV-infected patients exhibited down regulation of mannose receptor expression and reduced binding and phagocytosis of P. jirovecii . However, we did not detect a decrease in AM mannose receptor expression in P. jirovecii-infected patients, whatever their HIV serological status. Interestingly, we showed that dectin-1 expression on AM is increased when patients are infected with P. jirovecii . Dectin-1 plays a part in P. jirovecii nonopsonic phagocytosis, in the production of AM cytokine and reactive oxygen species [35] , and is particularly important in protection against P. jirovecii [37] . In a context of pulmonary defi ciency of the innate immunity (dramatic decrease in AM), this over-expression of AM dectin-1 may enhance the host defence against P. jirovecii .
Lymphocyte responses seem to be essential for fungal elimination during P. jirovecii infections [3] . Our study demonstrated that the alveolar lymphocyte count increased during this disease. This change occurs principally among CD3 ϩ T lymphocytes (CD8 ϩ and CD4 ϩ T lymphocytes). Previous studies of BAL lymphocytes, principally of HIV patients, have already shown an increase in the alveolar percentage of lymphocytes during P. jirovecii infections [25,27,38 -41] . Nevertheless, even if our study showed an overall increase in alveolar lymphocytes among P. jiroveciiinfected patients, we found that this lymphocyte count varied according to the P. jirovecii burden.
In our investigation, alveolar CD8 ϩ T cells increased locally and specifi cally in lung, whatever the fungal burden. Studies of HIV P. jirovecii-infected patients [38, 39, 42] or of SIV-Pneumocystis carinii -co-infected Rhesus Macaques [43] have provided similar results but its origin was not explained (HIV or Pneumocystis infection). Studying only HIV-negative patients, we have demonstrated that P. jirovecii infection is specifi cally associated with a CD8 ϩ T cell increase. In murine models, CD8 ϩ T cells that are recruited to the lung in large numbers in response to a P. jirovecii infection do not seem to be directly implicated in P. jirovecii clearance but rather have been associated with lung injury [9 -11] .
CD4 ϩ T cells play crucial roles in the host defence against Pneumocystis , both in humans [44, 45] and in animal models [7, 46] of infection, by stimulating and maximizing the immune system. PjP development in HIV-infected patients or after intratracheal instillation in mice depleted for CD4 ϩ T cells, proves the fundamental role of these cells in P. jirovecii infection pathophysiology. Recent studies in animals and humans, have begun to elucidate the mechanisms of the CD4 ϩ T-cell activation during P. jirovecii infection. In healthy individuals, the release of TNF-α and IL-1 by AM is required for the initiation of the CD4 ϩ T-cell response [47] . Moreover, CD4 ϩ T cells proliferate in response to Pneumocystis antigens and generate cytokines, including IFN-γ and lymphotactin [3, 48] required for additional lymphocyte recruitment [49] . Our results of the alveolar CD4 ϩ T cell count and the existence of an inverse correlation between the P. jirovecii burden and CD4 ϩ T cells were consistent with those of previous studies. The signifi cant increase in alveolar CD4 ϩ among patients with a low P. jirovecii burden refl ects a suffi cient proliferation and recruitment of these cells to maintain the fungal burden at a low level and to control the infection. Conversely, patients in the high burden group presented the same level of CD4 ϩ as the controls. No recruitment or proliferation of the CD4 ϩ , which were necessary for an appropriate anti-P. jirovecii immune response, occurred among these patients. This alveolar immunosuppression explains the high P. jirovecii burden observed in these patients. On this assumption, there could be an equilibrium in the aveoli of the lungs between the fungal concentration and CD4 ϩ T cell levels, underlined in this study by the inverse correlation between these two parameters. This strong and inverse correlation could be indicative of a more direct link between P. jirovecii and CD4 ϩ T cells than between P. jirovecii and AM.
The alveolar environment also showed changes in the cytokine profi le during P. jirovecii infection. Data have often been contradictory according to the study models (human or animal) or methodology [50 -53] . Moreover, many of the previous studies did not take into consideration the different BAL dilutions, which is why we used the urea method to avoid this bias. In rodent models of PjP, an increase in IL-10 and TNF-α has been observed [54 -56] but opposite results were obtained in rabbit models [48, 57, 58] . In humans, two ex vivo studies on HIVpositive or -negative patients with or without P. jirovecii infections did not demonstrate an increase in TNF-α or IL-10 release from BAL cells [52, 59] . Our study indicated that there were no differences in the alveolar IL-10 or TNF-α levels between patients with or without P. jirovecii infection. These results relative to the IL-10 and TNF-α concentrations are in agreement with the fi ndings reported by 59] or with rabbit models of P. jirovecii [48, 57, 58] . Knowing that macrophages are the main cells producing these two cytokines and which are also the majority of cells in BAL, we can postulate that the low level of TNF-α and IL10 is attributable to the diminution of macrophages in the alveolar compartment. This low level of cytokines may cause a disruption in the cytokine network and lead to a defi ciency in the immune response against P. jirovecii . The level of IL-6 was statistically higher in the P. jirovecii group. Although, this increase has been shown in many animal models of PjP [53, 54, 56, 60] , data on alveolar IL-6 concentrations in humans are extremely limited. Using the cell pellet or AM obtained from BAL fl uid, two studies showed that IL-6 production was not increased in vitro [52, 59] . The increase in alveolar IL-6 observed in vivo during P. jirovecii infection may originate from the production by P. jirovecii attachment to alveolar epithelial cells [61, 62] , rather than from the cells directly present in the BAL. A few data suggest that respiratory impairment and death are more closely correlated to the extent of lung infl ammation than to the burden of the etiologic agent during PjP [63] . Agusti et al . [64] have shown that IL-6 levels in BAL fl uid may help in the evaluation of the pulmonary infl ammatory response and may be an independent predictor of mortality. Therefore, IL-6 levels may play an important role in the pathophysiology of serious PjP.
IL-6 is also implicated in the recently described Th17 immune response which is reported to be involved in clearing fungal pathogens [17] . IL-6 and TGF-β stimulate naive CD4 ϩ T cells to differentiate into a novel subset called Th17 cells [65 -67] which are distinct from the classical Th1 and Th2 cells. Moreover, recent experimental and clinical studies have shown an important role of the Dectin-1 pathway in the differentiation of Th17 and Th1 CD4 ϩ T cells, particularly during fungal infections in vivo , and in humans [68] . Only two studies considered the Th17 response in animal models of P. jirovecii . The fi rst study indicated that in immunocompetent mice (nondepleted for CD4 ϩ T cells), lower levels of IL-17 in the lung resulted in a transient decrease in the clearance of Pneumocystis cells [69] . The second study suggested that IFN-γ was needed to suppress Th17 differentiation and that the Th17 response seemed to be ineffective against Pneumocystis infection in immunocompromised hosts [70] . To evaluate the alveolar Th17 response in humans, we measured TGF-β and IL-17 in ALF. Levels of TGF-β and IL-17 were not statistically different between the group of P. jirovecii -infected patients and the control groups. These data may mean that the Th17 response is not predominant in the pathophysiology of PjP or that this response is not directly observable by measuring IL-17 or TGF-β in the BAL (binding of IL-17 or TGF-β ). Moreover, these results were in apparent disagreement with the higher Dectin-1 expression on AM. The fi rst explanation could be that the Th17 response is independent of Dectin-1 during Pneumocystis infection. The second hypothesis is that the Th17 response depended on Dectin-1 but was disrupted in its development. Even if Dectin-1 was overexpressed during P. jirovecii infection, there was also a considerable decrease in AM numbers with an impairment of the function of these cells. As described in some studies for 72] , AM cytokine secretion and activation might be decreased, causing alterations in the interleukin collaboration and the ability to interact with lymphocytes to induce the Th17 response. Further studies will be necessary to better understand the role of this response in P. jirovecii infection both in the immunocompetent and immunocompromised host.
In summary, this study showed that human P. jirovecii infection was linked to changes in the local alveolar microenvironment. AM and lymphocytes play a major role in the pathophysiology of this disease. Even if there was an overall decrease in the AM with an increase in the alveolar lymphocytes, the count of these cells was very dependent on the P. jirovecii burden. There was an equilibrium between the alveolar immune impairment and the development of P. jirovecii . A severe pulmonary immunosuppression, associated with a very low level of AM and a lack of recruitment and proliferation of CD4 ϩ , led to a very high burden of P. jirovecii . The high level of IL-6 (probably secreted by alveolar epithelial cells) and of the CD8 ϩ T lymphocytes may also explain the pathophysiology of this infection by contributing to the infl ammation and to the development of the lung injury observed in this disease. Moreover, our study shows changes in the pulmonary environment, even for low P. jirovecii burdens. These low counts, clinically considered as colonization, involve an increase in the number of alveolar lymphocytes (CD8 ϩ and CD4 ϩ T cells), IL-6 level and Dectin-1 expression on AM. These pulmonary colonizations may stimulate infl ammation and may play a role in the development of lung diseases such as chronic obstructive pulmonary disease [73] .
